United Therapeutics (UTHR) CEO trades shares under Rule 10b5-1 plan in Dec 2025
Rhea-AI Filing Summary
United Therapeutics Corporation’s chairperson and CEO reported option exercises and related share sales in December 2025. On 12/11/2025 and 12/12/2025, the reporting person exercised stock options for 4,000 shares of common stock on each day at an exercise price of $120.26 per share and sold the same number of shares in the market.
The reported sales were executed at weighted average prices of $483.1213, $484.3036, $485.14, $489.9533 and $490.9772, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on May 2, 2025. Following these transactions, the reporting person holds 130 shares directly, 166 shares indirectly through a spouse, and additional indirect interests through several family trusts, including positions of 324,518, 258,117, 45,596 and 10,962 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,100 | $489.9533 | $539K |
| Sale | Common Stock | 2,900 | $490.9772 | $1.42M |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,500 | $483.1213 | $725K |
| Sale | Common Stock | 1,976 | $484.3036 | $957K |
| Sale | Common Stock | 524 | $485.14 | $254K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $482.98 to $483.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $484.00 to $484.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $489.49 to $490.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $490.885 to $491.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
FAQ
What insider transactions did United Therapeutics (UTHR) report for its CEO in December 2025?
The chairperson and CEO exercised stock options for 4,000 shares of United Therapeutics common stock on 12/11/2025 and another 4,000 shares on 12/12/2025 at an exercise price of $120.26 per share, and sold the same number of shares in market transactions on each date.
Were the UTHR CEO’s stock sales made under a Rule 10b5-1 trading plan?
Yes. The filing states that the option exercises and related share sales were carried out under a pre-arranged Rule 10b5-1 trading plan that the reporting person entered into on May 2, 2025.
What are the key terms of the CEO’s 10b5-1 trading plan for UTHR stock options?
The plan covers a tranche of 294,000 stock options expiring on March 15, 2026 and will continue until the earlier of the tranche’s exhaustion or December 31, 2025, according to the disclosure.
What type of derivative securities were involved in the United Therapeutics CEO’s transactions?
The transactions involved stock options to acquire United Therapeutics common stock at an exercise price of $120.26 per share. After the reported exercises, the CEO beneficially owned 22,000 options before and 18,000 options after the second exercise noted in the table.
How are the CEO’s family trust holdings in United Therapeutics structured?
The filing explains that multiple family trusts hold United Therapeutics shares, including trusts where the reporting person and immediate family are beneficiaries, and trusts where the spouse is trustee or co-trustee. Reported trust positions include 324,518, 258,117, 45,596 and 10,962 shares.